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Radiation oncologyBackground and purpose: Radiation oncology guidelines favour hypofractionated whole-breast radiother-
apy (HWBRT) over more conventional schemes in the conservative treatment of breast cancer, but its
adoption still varies in clinical practice. This study assessed the patterns of HWBRT adoption in
Catalonia (Spain).
Material and methods: We used a mixed-methods approach based on an explanatory sequential design,
first collecting and analysing quantitative data on HWBRT use (>2.5 Gy per fraction) in 11 public radio-
therapy centres (2005–2015) and then performing 25 semi-structured interviews with all department
heads and reference radiation oncologist/s.
Results: Of the 34,859 patients fulfiling the study criteria over the study period, just 12% were hypofrac-
tionated, reaching a percentage of 29% in 2015 (p < 0.001). Our analysis showed a narrowing age gap
between patients receiving conventional fractionation and hypofractionation in centres leading adoption.
However, there were important differences in clinicians’ interpretation of evidence (e.g. regarding the
perceived risk of long-term toxicity) and selection of patients for specific indications, both within and
between departments.
Conclusions: Differences observed in the rate of adoption of HWBRT could not be tackled only using a
rational, evidence-based approach. Factors related to the management of radiotherapy departments play
a major role in the diffusion of therapeutic strategies.
 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology xxx (2017) xxx–xxxA consolidated body of evidence [1–4] has shown that a high
proportion of breast cancer patients may achieve the same clinical
outcomes with 15–16 fractions (40–42.5 Gy) of postoperative
radiotherapy as with the longer conventional radiotherapy course
of 25 fractions. Randomized studies show that this conservative
regimen is more convenient for patients, incurs a lower cost for
the healthcare system, and causes less acute skin toxicity [5]. From
a cancer care policy standpoint, the American Society for Radiation
Oncology (ASTRO), the European Society for Radiotherapy &Oncology (ESTRO), and the National Institute for Health and Care
Excellence (NICE) all prefer the so-called modest hypofractionation
(2–3 Gy per fraction) [6] for most patients with early breast cancer,
recognizing the positive implications for health systems with high
caseloads of patients potentially undergoing such regimen. Indeed,
hypofractionation schedules reduce acute toxicity, which can lead
to discontinuation of radiotherapy treatment [7]. Despite the ben-
efits for patients and health systems and its consideration as a
standard of care [8,9], hypofractionated whole-breast radiotherapy
(HWBRT) still encounters resistance, and its adoption varies in
clinical practice [10,11].
Although other strategies—such as breast-intensity modulated
radiotherapy (IMRT)—have been adopted on the basis of lessr breast
2 Hypofractionated RT in breast cancerevidence and higher cost [12], some authors argue that random-
ized evidence and published guidelines alone are not sufficient
grounds to adopt HWBRT [10]. Past discussions regarding
tumour-grade sensitivity to hypofractionation [13,14], the unclear
effect of biological sub-types in the efficacy of the hypofractionated
schedule [8], or breast reconstruction [15] might be contributing to
the slow path of adoption and limited utilisation. Caution is still
warranted in patients under 40 and in those receiving primary sys-
temic treatment [16] or regional node irradiation (RNI) [17]. Thus,
particularly in a context in which the regional clinical guideline
does not specifically address this issue [18], departments may
interpret evidence for specific indications and nonclinical factors
differently, which would explain the existing variability in its
adoption.
Our study aims to provide an overview of the adoption of
hypofractionation for breast cancer in the Public Health Service
of Catalonia (Spain). We combine quantitative and qualitative
approaches to evaluate the evolution of its use from 2005 to
2015 and to explain the data from the perspective of radiation
oncologists involved in breast cancer treatment in the region.
Materials and methods
We used a mixed-methods approach based on an explanatory
sequential design, which consists of two different interactive
phases [19,20]. First we collected quantitative data on hypofrac-
tionation use; in light of the wide variation of our results, we added
a qualitative study in radiotherapy departments. Exploring partic-
ipants’ views in depth helped to explain statistical results by both
disentangling the specific indications described at each depart-
ment and the clinical rationale behind them [21]. Our final inter-
pretation and analysis considered the interaction between
quantitative and qualitative findings [22]. The reasons for mixing
quantitative and qualitative methods were completeness for a more
comprehensive account of the area of inquiry and discovery of
hypotheses [19].
We assessed the use of hypofractionation for the 11 public
radiotherapy centres in Catalonia (Spain), which provide oncology
treatments for a population of 7.5 million and comprise a total of
35 linear accelerators. The longest distance between the home of
an individual requiring radiation treatment in Catalonia and a facil-
ity is 170 km, while 80% of the population lives within 20 km. The
cost of treatments is reimbursed on the basis of four levels of com-
plexity, regardless of the fractions used.Quantitative assessment
We assessed the use of hypofractionation for patients receiving
breast cancer treatment with a curative intent in 2005–2015, using
data from the Catalonian Hospital Reimbursement Database, which
includes all patients receiving a course of radiotherapy. It collects
data on sex, age, radiotherapy centre, aim of treatment, tumour
site, total dose, planning system, initiation and finalisation of treat-
ment, and number of sessions. It is mandatory to fill out for reim-
bursement. The criterion for radiotherapy to be considered
hypofractionated was >2.5 Gy per fraction. The doses included in
this study ranged from 2.67 to 3.00 Gy. We assessed differences
in patterns of use with descriptive statistics and logistic regression,
using SPSS (version 21.0, 2012) and STATA (version 12) software.Qualitative assessment
The qualitative study consisted of 25 semi-structured on-site
interviews held in October–December 2015 with all department
heads and reference breast cancer radiation oncologist/s at each
hospital. One-on-one interviews ensured that all critical pointsPlease cite this article in press as: Prades J et al. Understanding variations in the
cancer: A mixed-methods study. Radiother Oncol (2017), http://dx.doi.org/10.1were addressed, and the 45–60 min sessions were flexible enough
to enable participants to volunteer information on topics relevant
to them. Only at the end of each interview was provided anon-
ymised information about the centre’s HWBRT utilisation relative
to other centres (Figs. 1 and 3). The evaluation of HWBRT, with
no comparative information, allowed us to limit the risk of infor-
mation bias and to contribute to the internal validity of the study
based on strictly local perspectives from each service. All inter-
views were audio-taped and transcribed [23]. These data were
then compiled into a documentary record and rendered
anonymous.
To analyse the data, we applied thematic-analysis criteria,
which emphasise the meaning of the text and interpret its the-
matic content [24,25]. After checking saturation of information
[26], we read through to identify general themes and thematic cat-
egories to ensure interpreter consensus. We compared interviews
to capture recurring views and related experiences [27]. A system-
atic process of data-treatment analysis was facilitated by the use of
the Atlas-ti 6.2 software [28]. Coding and interpretation consis-
tency was checked during analysis by reviewing the transcripts
at different moments in time.Results
Quantitative assessment
Of the 34,859 patients fulfiling the study criteria, only 4,322
(12.4%) breast cancer patients received hypofractionation in the
11 public radiotherapy departments in Catalonia in 2005–2015,
with important variations in use across departments (p < 0.001).
In 2015, 29% of patients received hypofractionated radiotherapy
(table 1). While the scheme (2.67–3.0 Gy) ranged from 1% to
36.6% in 2010 among different departments, these figures rose to
8.9% and 74.7% in 2015 (Fig. 1). The use of hypofractionation in
2015 exceeded 50% in two departments, while another five used
the therapy 25–50% of the time, and four others less than 25% of
the time.
Likewise, the median age of patients in 2015 appeared relevant
when deciding the regimen to be applied; the more hypofraction-
ation is used, the smaller the age difference between patients who
receive it and those who don’t (Fig. 2). By contrast, patients’ age
was near or over 70 years in the four departments with lower rates
of HWBRT use.
The trends in the adoption of hypofractionation varied signifi-
cantly by department, and in several individual cases we observed
a striking, non-linear behaviour (Fig. 3). Three milestones in this
time period frame the observed variability from a health system
perspective. First, three centres (1, 2 and 9) introduced hypofrac-
tionation in routine practice in 2008 and 2011, in one case it had
completely superseded the conventional scheme by 2015. Second,
2014–2015 seemed a turning point for many departments in the
adoption of hypofractionation, and 4 out of 11 showed utilisation
rates near 30%. Finally, by 2015, there were still four centres using
the technique less than 25% of the time, highlighting wide differ-
ences in use between centres.Qualitative assessment
The results of the quantitative assessment can be interpreted in
light of the criteria determining the use of hypofractionation in
each department. We analysed criteria concerning clinical factors
emerging from the interviews on the basis of specific indications
and created three categories to describe the use of hypofractiona-
tion in each department as physician-dependent, attributable to
most professionals (including the reference ones for breast cancer),
or with higher degree of homogeneity: a unified practice (Fig. 4).use of hypofractionated radiotherapy and its specific indications for breast
016/j.radonc.2017.01.014
Fig. 1. Hypofractionation use by department in 2010 and 2015.
Fig. 2. Median age of patients undergoing hypofractionated radiotherapy per department in 2010 and 2015.
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Fig. 3. Trends in use of hypofractionated whole-breast radiotherapy (HWBRT) by
department (2005–2015).
4 Hypofractionated RT in breast cancerThe second category responds to the fact that breast cancer is
rarely managed by only one or two radiation oncologists within
departments due to the high caseload.
The results show the differences observed across and within
clinical departments:Hypofractionation across clinical departments
‘‘Low-risk” patients
All interviewees pointed to the non-inferiority of hypofraction-
ation compared to the conventional schedule, although they dif-
fered as to whether the available evidence was qualitatively
consistent and sufficient to routinely adopt it. Most or all of the
so-called ‘low-risk’ patients, that is, those whose advanced age
put them at lower risk for the late side effects associated with lar-
ger doses of radiation therapy due to shorter life expectancy, were
hypofractionated in 9 out of 11 departments (Fig. 4). From a
chronological perspective, this is consistent with the two-wave
adoption process across providers: from older to younger patients
while extending indications. However, some radiation oncologists
restricted hypofractionated radiotherapy to very old patients with
transportation difficulties until as late as 2014, which is consistent
with the median age analysis (Fig. 2). In general, the potential cor-
relation between hypofractionation and long-term toxicity, espe-
cially cardiotoxicity, was a major cross-cutting concern among
clinicians. Indeed, two clinicians openly explained reverting to
the conventional schedule when their patients experienced toxici-
ties after the course of the treatment.
Chemotherapy and trastuzumab (TTZ)
One set of indications with important differences between pro-
viders was for patients receiving chemotherapy with or without
TTZ. For most professionals, combination hypofractionation plusTable 1
Hypofractionated radiotherapy treatments for the period 2005–2015 and adjusted OR for
Year <2.5 Gy/fraction 2.5 G
N % N
2005 2019 93.3 146
2006 2673 92.8 207
2007 2748 94.1 171
2008 2913 95.9 123
2009 3064 93.1 228
2010 3038 91.5 284
2011 3106 86.7 478
2012 2833 85.1 495
2013 2974 84.3 552
2014 2803 80.7 672
2015 2366 71.0 966
TOTAL 30537 87.6 4322
Footnote: OR: odds ratio. CI 95%: confidence interval. Logistic regression model adjusted
Please cite this article in press as: Prades J et al. Understanding variations in the
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age, while a few accepted the schedule of 40–42 Gy delivered in
15–16 fractions. However, within this favourable group, some con-
sidered primary systemic treatment ‘‘an indicator of intermediate
toxicity” and only hypofractionated patients with adjuvant
chemotherapy. Others included only patients receiving neoadju-
vant treatment, arguing that ‘‘a longer time-lapse between
chemotherapy and radiotherapy decreases the possibility of inter-
action and chronic toxicity”.
Interestingly, many professionals stressed changing their opin-
ion over time on the potential interaction between chemotherapy
and hypofractionation. Reasons included RCT findings on car-
diotoxicity during follow-up, the significant positioning of ASTRO,
and particularly, their observance of equivalent or lower short-
and medium-term toxicity in their patients compared to the con-
ventional scheme.
Left-sided breast and RNI irradiation
Other important points involved hypofractionation of the ‘left-
sided breast’ and of RNI. The former case clearly showed that pro-
fessionals do not adopt hypofractionation unless they consider it a
comprehensive alternative in whole-breast radiation, even with
theoretical modelling showing similar local control when avoiding
irradiation in part of the breast. Clinicians saw the following situ-
ations as problematic: the concomitant application of other radio-
therapy techniques to avoid heart irradiation and/or the need to
avoid late side effects in women with other risk factors such as
hypertension or cholesterol.
In the case of RNI, almost all interviewees referred to the lack of
sufficient evidence to routinely adopt it, while a few pointed out
that no studies have disproven increased normal tissue effects of
the brachial plexus, and there are consistent reports of successful
case-by-case hypofractionation.
Large/pendulous breasts, grade 3, breast cancer sub-types and chest
wall
A third set of indications gathered situations like ‘‘large/pendu-
lous breasts”, ‘‘grade 3”, ‘‘breast cancer sub-types” or ‘‘chest wall”.
These patients were mainly hypofractionated in centres where this
was the prevailing scheme. Elsewhere, hypofractionating these
patients added another layer of complexity for clinicians on top
of other ‘‘controversial” situations (e.g. chemotherapy, carcinoma
in-situ) or techniques, for instance, using respiratory-gated radia-
tion or decubitus prone position in the event of a large breast in
order to better homogenise the dose.
Boost irradiation
Hypofractionation of the tumour bed boost also deserves a
mention. Some professionals lamented the ‘‘original sin” of pivotalthe annual trend of utilisation.
y/fraction OR 95% CI
%
6.7 1
7.2 1.09 0.86–1.38
5.9 0.92 0.72–1.18
4.1 0.63 0.49–0.82
6.9 1.12 0.89–1.41
8.5 1.52* 1.22–1.90
13.3 2.85* 2.31–3.51
14.9 3.08* 2.49–3.80
15.7 3.56* 2.89–4.38
19.3 5.15* 4.20–6.33
29.0 9.91* 8.09–12.13
12.4
for patient age and department. *p < 0.001 compared to reference year (2005).
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Radiaon oncology departments (D1-D11)
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11
Speciﬁc indicaons*
Youngest paents’ by protocol < 45 45 50 50 50 70 - 70 50 50 -
“Low risk” paentsa
Adjuvant chemotherapy  
Neoadjuvant chemotherapy  
Le sided breast
RNI
Large/pendulous breasts
All biological BC sub-types  
Grade 3
Chest wall
Categories of use a Paent ≥70 year-old with conservave surgery, stages I-II, free 
margins, negave nodes, posive receptor, and no le-breast 
irradiaon. 
* Including excepons related to each paent proﬁle (e.g. 
neoadjuvant chemotherapy for le-sided breast) depending on the 
physician/department.
Not indicated
Physician-dependent
Mostly indicated
Uniﬁed pracce
Fig. 4. Categories of use of breast cancer hypofractionation by specific indication at clinical department level (November 2015).
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excluding hypofractionation, which paved the way for subsequent
misinterpretation and variability at health system level.Hypofractionation within clinical departments
Clinical factors
An inconsistent use of hypofractionation was shown in four
departments (3, 4, 6 and 9) in which the category ‘‘physician-dep
endent” matched most of the indications used (Fig. 4). Likewise,
departments treating fewer patients (6, 8 and 10) also failed to
unify practice. Some department heads drew a contrast with pros-
tate cancer, approached in a more homogeneous way since the
beginning. The use of hypofractionation with patients who
received chemotherapy was the main source of intra-department
variability; this was clear in 5 of the 11 departments (Fig. 4).
Clinical management factors
Management and cultural factors also influenced the adoption
of hypofractionation. Besides the (widely acknowledged) inertia
existing in clinical departments, many professionals saw hypofrac-
tionation as ‘‘something to believe”. Respondents pointed to four
factors:
(1) The role played by the department heads: Some heads oper-
ated under the assumption that clinical practice should be
homogenous within a single department, and they deliber-
ately stimulated innovative behaviours, while others decen-
tralised these management decisions to specialists. Several
respondents in low-hypofractionating departments associ-
ated clinical excellence and traditional approaches with
statements such as, ‘‘We have good clinical outcomes com-
pared to international experiences”. Physicians who had
worked in other centres were privileged witnesses to the
impact of organisational culture on physicians’ use of vary-
ing radiation schemes.
(2) The place of hypofractionation in the clinical protocol: While
most departments considered hypofractionation to be one
‘‘possibility of two alternatives” in accordance with their
protocol, one gave it ‘‘priority over the conventional sched-
ule”. A third type of protocol restricted its use to specific
cases ‘‘up to [the protocol’s] comprehensive update”, thatPlease cite this article in press as: Prades J et al. Understanding variations in the
cancer: A mixed-methods study. Radiother Oncol (2017), http://dx.doi.org/10.1is, once every 1–2 years, making the timing of this revision
a barrier for introducing new schemes. Notably, some
departments set a minimum patient age of 50 for hypofrac-
tionation (Fig. 2); however, the median age analysis showed
that it was delivered (in some cases almost exclusively) to
patients over 70 (Fig. 1).
(3) Ties between radiation specialists: Respondents mostly
appraised professional ties as a failed driver in adopting
hypofractionation. Young physicians stressed the need to
improve communication and overcome the current silo-
based departmental model.
(4) Change of pattern in machine use: Changes in machine usage
due to routine hypofractionation are considered relevant,
though it is unclear whether this would increase or decrease
use.
Discussion
This study assessed the patterns of use and adoption of HWBRT
for the conservative treatment of breast cancer in the public
healthcare sector of Catalonia (Spain) from 2005 to 2015. This is
an example of diffusion of change in practice where no specific
indications for this treatment have been established by the regio-
nal clinical guideline. Although use of HWBRT is increasing
region-wide, important variations remain in the rate of adoption,
which ranged from 8.9% to 74.7% in 2015. A population-based
study in New SouthWales (Australia) [11] showed similar findings,
reporting an average rate of utilisation of 35% (compared to 29% for
2015 in our study) and variability in the rates of adoption among
departments, ranging from 6% to 92% for 2007–2012. In our study,
the time-frame 2014–2015 seemed to be a turning point towards
the mainstream adoption of hypofractionation, although only 2
out of 11 departments used it more than 50% of the time, and 4
others basically limited hypofractionation to patients over 70,
highlighting how far this regimen is from being considered a rou-
tine practice. The qualitative analysis identified barriers to its
uptake for particular indications and illustrated how frequently
its use depends on physicians’ prerogative.
The integration of both quantitative and qualitative strands of
research allowed us to identify three patterns for adopting
hypofractionation among all radiotherapy departments:use of hypofractionated radiotherapy and its specific indications for breast
016/j.radonc.2017.01.014
6 Hypofractionated RT in breast canceraccelerated adoption, involving the substitution of conventional
treatment (dept. 1, 2 and 9); progressive adoption, showing the
coexistence between radiation schemes (dept. 3, 4, 5 and 7); and
experimental adoption, based on case-by-case hypofractionation,
mainly in elderly (>70 years) patients (dept., 6, 8, 10 and 11). These
results suggest that understanding the Diffusion of Innovations
theory may shed light on how hypofractionation is adopted across
the health systems [29]. For instance, this theory suggests that the
passage of time would interact with external and internal influ-
ences (e.g. perceived efficiency gained in relation to the classical
scheme, specific recommendations at international level, less acute
toxicity observed, etc.) and stimulate adoption of the innovation in
2014 by the so-called ‘early majority’ of five departments.
To speed up the dissemination process, Chapman et al. [30]
described the phased implementation of a 5-year clinical pathway
for breast radiation therapy that increased the utilisation rates
from 8.3% to over 75%. In Catalonia, our analysis revealed that
while indications were not mutually exclusive, chemotherapy with
or without TTZ worked as a stopcock within them, especially for
women under 70. The hypofractionation of patients receiving
chemotherapy and, similarly, the occurrence of long-term toxicity,
was the main point of disagreement among clinicians and source of
variability in clinical practice at intra- and inter-department levels.
As half of all breast cancer patients fall into these categories, their
inclusion in a hypofractionated regimen is a decisive determinant
of its overall use. The DBCG HYPO randomized clinical trial pro-
vides new evidence on this issue by including 36% of patients with
chemotherapy, with no associated increase in toxicity [31].
Nevertheless, the analysis of clinicians’ rationale highlighted
the importance of interpreting hypofractionation use in the con-
text of the specific indications rather than from a broader perspec-
tive. Specialists’ views sometimes reflected discrepancies already
discussed in the literature, such as with RNI or tumour-grade sen-
sitivity [13,14,32]. Strikingly, in other situations clinicians shared
interpretation of the evidence, for example agreeing that theoreti-
cal modelling showed similar local control on avoiding irradiation
in part of the left-sided breast, but clinical practice differed any-
way. There are two ways of understanding this phenomenon: first,
although Delaney and colleagues indicated that newer techniques,
such as deep inspiration breath-hold techniques to decrease the
risk of heart damage, should diminish concerns [11], some clini-
cians perceived these concomitant techniques as ‘‘another layer
of complexity”, and they seemed to slow HWBRT’s uptake. Second
and more relevantly, quality of evidence is a necessary but not a
sufficient condition determining clinicians’ behaviour towards
hypofractionation. Clinical management factors, such as the role
of the department head, played a key role in explaining the adop-
tion of this therapeutic strategy, for example in the D1 depart-
ment’s sudden increase in use in 2011 (Fig. 3).
The HWBRT has proven to be a controversial therapeutic strat-
egy in its implementation, leading to different rhythms of adoption
and characterised by intra- and inter-department variability. Clin-
icians suggested during discussions that an updated clinical guide-
line would contribute to homogenising clinical practice and/or
addressing treatments’ cost-effectiveness, thus contributing to
streamlining a process of decision-making currently restricted to
clinicians’ criteria. Furthermore, some authors noted that there is
no reason to assume that this approach is limited to modest
hypofractionation (15–16-fraction regimen) [6], so changes in this
regard would eventually widen the existing gap between early
and late adopters.
This study has some strengths and limitations. Regarding the
quality of the quantitative data, we used a specific registry cover-
ing all the radiotherapy departments in Catalonia, whose compre-
hensiveness is reinforced through linkage to treatment
reimbursement. We also performed statistical analyses using dataPlease cite this article in press as: Prades J et al. Understanding variations in the
cancer: A mixed-methods study. Radiother Oncol (2017), http://dx.doi.org/10.1exclusively from the public sector (responsible for providing more
than 85% of services). One limitation was that clinical factors such
as patient stage or chemotherapy indication were not taken into
account.
Strengths of the qualitative study were the comprehensive sam-
ple, including all department heads and reference specialists for
breast cancer. As far as limitations are concerned, unlike other
studies [10,33], we did not approach the topic of travel, although
one hospital raised the issue due to its geographic location. More-
over, in contrast to other experiences [34–36], neither financial
pressures nor waiting lists were of relevance in the analysis of
the adoption of hypofractionation.
In conclusion, the clinical practice of breast cancer hypofrac-
tionation showed considerable variability due to both provider-
based factors and along the course of adoption in the Catalonian
NHS. These differences are rooted in clinicians’ interpretation of
the evidence, especially concerning potential long-term toxicity,
but also in relation to context-dependent factors that significantly
favoured or hindered professional trust towards this new scheme.
In tackling with differences in the rate of adoption of HWBRT at the
health system level, a rational, evidence-based approach should
ideally converge with professional perspectives, the factors influ-
encing the interpretation of the evidence, and the organisational
context, including existing dissemination channels.Role of the funding source
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